BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38588697)

  • 1. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer.
    Wasko UN; Jiang J; Dalton TC; Curiel-Garcia A; Edwards AC; Wang Y; Lee B; Orlen M; Tian S; Stalnecker CA; Drizyte-Miller K; Menard M; Dilly J; Sastra SA; Palermo CF; Hasselluhn MC; Decker-Farrell AR; Chang S; Jiang L; Wei X; Yang YC; Helland C; Courtney H; Gindin Y; Muonio K; Zhao R; Kemp SB; Clendenin C; Sor R; Vostrejs WP; Hibshman PS; Amparo AM; Hennessey C; Rees MG; Ronan MM; Roth JA; Brodbeck J; Tomassoni L; Bakir B; Socci ND; Herring LE; Barker NK; Wang J; Cleary JM; Wolpin BM; Chabot JA; Kluger MD; Manji GA; Tsai KY; Sekulic M; Lagana SM; Califano A; Quintana E; Wang Z; Smith JAM; Holderfield M; Wildes D; Lowe SW; Badgley MA; Aguirre AJ; Vonderheide RH; Stanger BZ; Baslan T; Der CJ; Singh M; Olive KP
    Nature; 2024 May; 629(8013):927-936. PubMed ID: 38588697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-selective effects of active RAS inhibition in pancreatic ductal adenocarcinoma.
    Wasko UN; Jiang J; Curiel-Garcia A; Wang Y; Lee B; Orlen M; Drizyte-Miller K; Menard M; Dilly J; Sastra SA; Palermo CF; Dalton T; Hasselluhn MC; Decker-Farrell AR; Chang S; Jiang L; Wei X; Yang YC; Helland C; Courtney H; Gindin Y; Zhao R; Kemp SB; Clendenin C; Sor R; Vostrejs W; Amparo AA; Hibshman PS; Rees MG; Ronan MM; Roth JA; Bakir B; Badgley MA; Chabot JA; Kluger MD; Manji GA; Quintana E; Wang Z; Smith JAM; Holderfield M; Wildes D; Aguirre AJ; Der CJ; Vonderheide RH; Stanger BZ; Singh M; Olive KP
    bioRxiv; 2023 Dec; ():. PubMed ID: 38105998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers.
    Jiang J; Jiang L; Maldonato BJ; Wang Y; Holderfield M; Aronchik I; Winters IP; Salman Z; Blaj C; Menard M; Brodbeck J; Chen Z; Wei X; Rosen MJ; Gindin Y; Lee BJ; Evans JW; Chang S; Wang Z; Seamon KJ; Parsons D; Cregg J; Marquez A; Tomlinson ACA; Yano JK; Knox JE; Quintana E; Aguirre AJ; Arbour KC; Reed A; Gustafson WC; Gill AL; Koltun ES; Wildes D; Smith JAM; Wang Z; Singh M
    Cancer Discov; 2024 Jun; 14(6):994-1017. PubMed ID: 38593348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.
    Holderfield M; Lee BJ; Jiang J; Tomlinson A; Seamon KJ; Mira A; Patrucco E; Goodhart G; Dilly J; Gindin Y; Dinglasan N; Wang Y; Lai LP; Cai S; Jiang L; Nasholm N; Shifrin N; Blaj C; Shah H; Evans JW; Montazer N; Lai O; Shi J; Ahler E; Quintana E; Chang S; Salvador A; Marquez A; Cregg J; Liu Y; Milin A; Chen A; Ziv TB; Parsons D; Knox JE; Klomp JE; Roth J; Rees M; Ronan M; Cuevas-Navarro A; Hu F; Lito P; Santamaria D; Aguirre AJ; Waters AM; Der CJ; Ambrogio C; Wang Z; Gill AL; Koltun ES; Smith JAM; Wildes D; Singh M
    Nature; 2024 May; 629(8013):919-926. PubMed ID: 38589574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
    Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
    Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting mTOR dependency in pancreatic cancer.
    Morran DC; Wu J; Jamieson NB; Mrowinska A; Kalna G; Karim SA; Au AY; Scarlett CJ; Chang DK; Pajak MZ; ; Oien KA; McKay CJ; Carter CR; Gillen G; Champion S; Pimlott SL; Anderson KI; Evans TR; Grimmond SM; Biankin AV; Sansom OJ; Morton JP
    Gut; 2014 Sep; 63(9):1481-9. PubMed ID: 24717934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function.
    Viale A; Pettazzoni P; Lyssiotis CA; Ying H; Sánchez N; Marchesini M; Carugo A; Green T; Seth S; Giuliani V; Kost-Alimova M; Muller F; Colla S; Nezi L; Genovese G; Deem AK; Kapoor A; Yao W; Brunetto E; Kang Y; Yuan M; Asara JM; Wang YA; Heffernan TP; Kimmelman AC; Wang H; Fleming JB; Cantley LC; DePinho RA; Draetta GF
    Nature; 2014 Oct; 514(7524):628-32. PubMed ID: 25119024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer.
    Stellas D; Szabolcs M; Koul S; Li Z; Polyzos A; Anagnostopoulos C; Cournia Z; Tamvakopoulos C; Klinakis A; Efstratiadis A
    J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25306215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
    Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment.
    Klomp JE; Lee YS; Goodwin CM; Papke B; Klomp JA; Waters AM; Stalnecker CA; DeLiberty JM; Drizyte-Miller K; Yang R; Diehl JN; Yin HH; Pierobon M; Baldelli E; Ryan MB; Li S; Peterson J; Smith AR; Neal JT; McCormick AK; Kuo CJ; Counter CM; Petricoin EF; Cox AD; Bryant KL; Der CJ
    Cell Rep; 2021 Nov; 37(9):110060. PubMed ID: 34852220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Critical role of oncogenic KRAS in pancreatic cancer (Review).
    Liu J; Ji S; Liang C; Qin Y; Jin K; Liang D; Xu W; Shi S; Zhang B; Liu L; Liu C; Xu J; Ni Q; Yu X
    Mol Med Rep; 2016 Jun; 13(6):4943-9. PubMed ID: 27121414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.
    Zhao X; Wang X; Fang L; Lan C; Zheng X; Wang Y; Zhang Y; Han X; Liu S; Cheng K; Zhao Y; Shi J; Guo J; Hao J; Ren H; Nie G
    Cancer Lett; 2017 Aug; 402():61-70. PubMed ID: 28576749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PIN1 Maintains Redox Balance via the c-Myc/NRF2 Axis to Counteract Kras-Induced Mitochondrial Respiratory Injury in Pancreatic Cancer Cells.
    Liang C; Shi S; Liu M; Qin Y; Meng Q; Hua J; Ji S; Zhang Y; Yang J; Xu J; Ni Q; Li M; Yu X
    Cancer Res; 2019 Jan; 79(1):133-145. PubMed ID: 30355620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
    Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
    Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KRAS-related proteins in pancreatic cancer.
    Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG
    Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic blocking of RAS downstream signaling and epigenetic pathway in
    Zhang X; Mao T; Xu H; Li S; Yue M; Ma J; Yao J; Wang Y; Zhang X; Ge W; Wang Y; Shentu D; Wang L
    Aging (Albany NY); 2022 Apr; 14(8):3597-3606. PubMed ID: 35468095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic Rewiring by Loss of Sirt5 Promotes Kras-Induced Pancreatic Cancer Progression.
    Hu T; Shukla SK; Vernucci E; He C; Wang D; King RJ; Jha K; Siddhanta K; Mullen NJ; Attri KS; Murthy D; Chaika NV; Thakur R; Mulder SE; Pacheco CG; Fu X; High RR; Yu F; Lazenby A; Steegborn C; Lan P; Mehla K; Rotili D; Chaudhary S; Valente S; Tafani M; Mai A; Auwerx J; Verdin E; Tuveson D; Singh PK
    Gastroenterology; 2021 Nov; 161(5):1584-1600. PubMed ID: 34245764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF.
    Blasco MT; Navas C; Martín-Serrano G; Graña-Castro O; Lechuga CG; Martín-Díaz L; Djurec M; Li J; Morales-Cacho L; Esteban-Burgos L; Perales-Patón J; Bousquet-Mur E; Castellano E; Jacob HKC; Cabras L; Musteanu M; Drosten M; Ortega S; Mulero F; Sainz B; Dusetti N; Iovanna J; Sánchez-Bueno F; Hidalgo M; Khiabanian H; Rabadán R; Al-Shahrour F; Guerra C; Barbacid M
    Cancer Cell; 2019 Apr; 35(4):573-587.e6. PubMed ID: 30975481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of DNA-alkylating pyrrole-imidazole polyamides for anti-cancer drug sensitivity screening in pancreatic ductal adenocarcinoma.
    Tsujimoto A; Matsuo N; Lai X; Inoue T; Yoda H; Lin J; Shinozaki Y; Watanabe T; Koshikawa N; Takatori A; Nagase H
    Cancer Med; 2023 Mar; 12(5):5821-5832. PubMed ID: 36262061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRas4B-PDE6δ complex stabilization by small molecules obtained by virtual screening affects Ras signaling in pancreatic cancer.
    Casique-Aguirre D; Briseño-Díaz P; García-Gutiérrez P; la Rosa CHG; Quintero-Barceinas RS; Rojo-Domínguez A; Vergara I; Medina LA; Correa-Basurto J; Bello M; Hernández-Rivas R; Del RocioThompson-Bonilla M; Vargas M
    BMC Cancer; 2018 Dec; 18(1):1299. PubMed ID: 30594165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.